Technical Analysis for RVMD - Revolution Medicines, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 42.44 | 1.68% | 0.70 |
RVMD closed up 1.7 percent on Thursday, March 4, 2021, on 1.93 times normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Historical RVMD trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
50 DMA Resistance | Bearish | -0.02% | |
Pocket Pivot | Bullish Swing Setup | -0.02% | |
Stochastic Reached Oversold | Weakness | -0.02% | |
Wide Bands | Range Expansion | -0.02% | |
Oversold Stochastic | Weakness | -0.02% | |
Fell Below 50 DMA | Bearish | 1.68% | |
MACD Bearish Centerline Cross | Bearish | 1.68% | |
Wide Bands | Range Expansion | 1.68% | |
Inside Day | Range Contraction | -7.09% | |
Fell Below 20 DMA | Bearish | -6.04% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
Down 2 % | about 7 hours ago | |
Fell Below Previous Day's Low | about 7 hours ago | |
60 Minute Opening Range Breakdown | about 7 hours ago | |
Possible Pocket Pivot | about 7 hours ago | |
50 DMA Resistance | about 8 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Pharmacology Cancer Treatment Medical Terminology Signal Transduction mTOR Combination Therapy
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Pharmacology Cancer Treatment Medical Terminology Signal Transduction mTOR Combination Therapy
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 56.18 |
52 Week Low | 17.345 |
Average Volume | 578,662 |
200-Day Moving Average | 35.95 |
50-Day Moving Average | 43.79 |
20-Day Moving Average | 47.46 |
10-Day Moving Average | 44.62 |
Average True Range | 3.21 |
ADX | 16.7 |
+DI | 14.06 |
-DI | 24.60 |
Chandelier Exit (Long, 3 ATRs ) | 46.55 |
Chandelier Exit (Short, 3 ATRs ) | 50.40 |
Upper Bollinger Band | 55.00 |
Lower Bollinger Band | 39.92 |
Percent B (%b) | 0.17 |
BandWidth | 31.79 |
MACD Line | -0.33 |
MACD Signal Line | 0.45 |
MACD Histogram | -0.7887 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 48.00 | ||||
Resistance 3 (R3) | 48.06 | 46.26 | 47.08 | ||
Resistance 2 (R2) | 46.26 | 44.85 | 46.24 | 46.77 | |
Resistance 1 (R1) | 44.36 | 43.98 | 45.31 | 44.30 | 46.46 |
Pivot Point | 42.56 | 42.56 | 43.04 | 42.54 | 42.56 |
Support 1 (S1) | 40.66 | 41.15 | 41.61 | 40.60 | 38.44 |
Support 2 (S2) | 38.86 | 40.28 | 38.84 | 38.13 | |
Support 3 (S3) | 36.96 | 38.86 | 37.83 | ||
Support 4 (S4) | 36.90 |